Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
